Indication: Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A,), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE

Previously Treated with Trastuzumab and Taxane

Sub-indication: Metastatic/Unresectable HER2 positive 2nd line- (previous treatment of trastuzumab and taxane)

Line of Therapy: metastatic/unresectable HER2 positive 2nd line (previous treatment of trastuzumab and taxane)

Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: Daiichi Sankyo Company, Limited

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.